Intended use Diagnosis and treatment of the Thyroid Gland: for assessing the functional state of the thyroid gland, performing thyroid gland scans and scintigraphy for various conditions, including diagnosing thyroid dysfunction, as well as well-differentiated thyroid cancer and metastases. For therapeutic purposes, the medication is used in treating hyperthyroidism and metastases of thyroid cancer
Grade: 1. Non-carrier added radionuclide; 2. GMP product; 3. Tested for sterility and bacterial endotoxins
Chemical form: ¹³¹I in 0.1M NaOH solution | ¹³¹I, carrier free, in 0.05M NaOH solution containing 0.001M Na₂S₂O₃ Appearance: transparent, colourless liquid Half-life period: 8.02 days Radiochemical purity, %: ≥ 95 | ≥ 98 Radioactive concentration, mCi/ml: ≥ 2000.0 Specific activity, Ci/mg: > 6.5